MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 3.30 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-05
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 995.02K shares, a 79.50% decline year-over-year.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 2.31M shares, a 200.66% increase year-over-year.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 2.43M shares, a 168.94% increase year-over-year.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 625.34K shares, a 159.21% increase year-over-year.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 8.67M shares, a 23.17% increase from fiscal 2024.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 7.04M shares, a 6.51% decline from fiscal 2023.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 7.53M shares, a 47.08% increase from fiscal 2022.
- MANNKIND CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 5.12M shares, a 53.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 995.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 3.30M shares 10-Q · filed 2026-08-05 | 5.73M shares derived: sum of 3 quarters · filed 2026-08-05 | 6.35M shares derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | 2.31M shares 10-Q · filed 2026-05-06 | 4.73M shares derived: sum of 2 quarters · filed 2026-05-06 | 5.36M shares derived: sum of 3 quarters · filed 2026-05-06 | 10.21M shares derived: sum of 4 quarters · filed 2026-05-06 | |
| 2025-12-31 | 2.43M shares derived: 10-K 12 month − 3 quarters · filed 2026-02-26 | 3.05M shares derived: sum of 2 quarters · filed 2026-02-26 | 7.91M shares derived: sum of 3 quarters · filed 2026-02-26 | 8.67M shares 10-K · filed 2026-02-26 | |
| 2025-09-30 | 625.34K shares 10-Q · filed 2025-11-05 | 5.48M shares derived: sum of 2 quarters · filed 2025-11-05 | 6.25M shares derived: sum of 3 quarters · filed 2025-11-05 | 7.15M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 4.85M shares 10-Q · filed 2025-11-05 | 5.62M shares derived: sum of 2 quarters · filed 2025-11-05 | 6.52M shares derived: sum of 3 quarters · filed 2025-11-05 | 6.76M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-03-31 | 767.35K shares 10-Q · filed 2025-11-05 | 1.67M shares derived: sum of 2 quarters · filed 2025-11-05 | 1.91M shares derived: sum of 3 quarters · filed 2025-11-05 | 7.54M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-12-31 | 901.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 1.14M shares derived: sum of 2 quarters · filed 2025-02-26 | 6.77M shares derived: sum of 3 quarters · filed 2025-02-26 | 7.04M shares 10-K · filed 2025-02-26 | |
| 2024-09-30 | 241.25K shares 10-Q · filed 2024-11-07 | 5.87M shares derived: sum of 2 quarters · filed 2024-11-07 | 6.14M shares 10-Q · filed 2024-11-07 | 9.03M shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | 5.63M shares 10-Q · filed 2024-11-07 | 5.90M shares 10-Q · filed 2024-08-07 | 8.79M shares derived: sum of 3 quarters · filed 2024-11-07 | 8.82M shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-03-31 | 267.99K shares 10-Q · filed 2024-11-07 | 3.16M shares derived: sum of 2 quarters · filed 2024-11-07 | 3.19M shares derived: sum of 3 quarters · filed 2024-11-07 | 7.62M shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | 2.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 2.93M shares derived: sum of 2 quarters · filed 2024-02-27 | 7.35M shares derived: sum of 3 quarters · filed 2024-02-27 | 7.53M shares 10-K · filed 2024-02-27 | |
| 2023-09-30 | 34.38K shares 10-Q · filed 2023-11-07 | 4.46M shares derived: sum of 2 quarters · filed 2023-11-07 | 4.64M shares 10-Q · filed 2023-11-07 | -4.87B shares derived: sum of 4 quarters · filed 2023-11-07 | |
| 2023-06-30 | 4.43M shares 10-Q · filed 2023-11-07 | 4.61M shares 10-Q · filed 2023-08-07 | -4.87B shares derived: sum of 3 quarters · filed 2023-11-07 | -3.97B shares derived: sum of 4 quarters · filed 2023-11-07 | |
| 2023-03-31 | 179.91K shares 10-Q · filed 2023-11-07 | -4.88B shares derived: sum of 2 quarters · filed 2023-11-07 | -3.97B shares derived: sum of 3 quarters · filed 2023-11-07 | -83.11M shares derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-12-31 | -4.88B shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -3.97B shares derived: sum of 2 quarters · filed 2023-02-23 | -83.29M shares derived: sum of 3 quarters · filed 2023-02-23 | 5.12M shares 10-K · filed 2023-02-23 | |
| 2022-09-30 | 904.43M shares 10-Q · filed 2022-11-08 | 4.79B shares derived: sum of 2 quarters · filed 2022-11-08 | 4.88B shares 10-Q · filed 2022-11-08 | 1.72B shares derived: sum of 4 quarters · filed 2022-11-08 | |
| 2022-06-30 | 3.89B shares 10-Q · filed 2022-11-08 | 3.98B shares 10-Q · filed 2022-08-09 | 819.35M shares derived: sum of 3 quarters · filed 2022-11-08 | 899.72M shares derived: sum of 4 quarters · filed 2022-11-08 | |
| 2022-03-31 | 88.42M shares 10-Q · filed 2022-11-08 | -3.07B shares derived: sum of 2 quarters · filed 2022-11-08 | -2.99B shares derived: sum of 3 quarters · filed 2022-11-08 | -278.40M shares derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-12-31 | -3.16B shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -3.08B shares derived: sum of 2 quarters · filed 2022-02-24 | -366.81M shares derived: sum of 3 quarters · filed 2022-02-24 | 3.33M shares 10-K · filed 2022-02-24 | |
| 2021-09-30 | 80.37M shares 10-Q · filed 2021-11-09 | 2.79B shares derived: sum of 2 quarters · filed 2021-11-09 | 3.16B shares 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | 2.71B shares 10-Q · filed 2021-11-09 | 3.08B shares 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | 370.14M shares 10-Q · filed 2021-11-09 | ||||
| 2020-12-31 | 7.01M shares 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | 1.29M shares 10-K · filed 2020-02-25 | ||||
| 2018-12-31 | 448.60K shares 10-K · filed 2019-02-26 | ||||
| 2017-12-31 | 669.09K shares 10-K · filed 2018-02-27 | ||||
| 2016-12-31 | 800.53K shares 10-K · filed 2017-03-16 | ||||
| 2015-12-31 | 1.13M shares 10-K · filed 2016-03-15 | ||||
| 2014-12-31 | 954.13K shares 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | 8.48M shares 10-K · filed 2014-03-03 | ||||
| 2012-12-31 | 1.37M shares 10-K · filed 2013-03-18 | ||||
| 2011-03-03 | 1.18M shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |